Budenofalk shortage — CH supply status & alternatives

Budenofalk

—

🇦🇺 AUST R 179575

In supply · Australia

In supply · 🇦🇺 Australia · short in🇨🇭 CH🌐 SK

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Budenofalk
Therapeutic category	Auto-created by Swissmedic scraper
Controlled substance	No
Marketing-authorisation holders	DR FALK PHARMA GMBH

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇨🇭 1 July 2026

medium reported

🇨🇭 28 June 2026

medium reported

🇨🇭 27 June 2026

medium reported

🇨🇭 26 June 2026

medium reported

🇨🇭 22 June 2026

medium reported

🇨🇭 21 June 2026

medium reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders5 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
BUDENOFALK 3MG GASTRO-RESISTANT CAPSULES	3MG	capsule	🇬🇧 GB	DR FALK PHARMA GMBH	Active
BUDENOFALK 2MG/DOSE RECTAL FOAM	2MG	budenofalk	🇬🇧 GB	DR FALK PHARMA GMBH	Active
BUDENOFALK 9MG GASTRO-RESISTANT GRANULES	9MG	budenofalk	🇬🇧 GB	DR FALK PHARMA GMBH	Active
BUDENOFALK budesonide foam	2 mg	—	🇦🇺 AU	—	Active
BUDENOFALK budesonide	3 mg	—	🇦🇺 AU	—	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.